However, the chemotherapy resistance and dose-limiting toxicity of irinotecan restrict its clinical application, such as drug resistance in patients with advanced non-small cell lung cancer (NSCLC) associated with ATP binding cassette subfamily G member 2 (ABCG2), breast cancer drug resistance induced by regulation of cell cycle and DNA repair activity [3], delayed-onset diarrhea and neutropenia [4]. Here, ABCG2 is linked to non-small cell lung carcinoma.